



Antibody-Drug Conjugates—a Coming of Age

Guest Editor:

Prof. Dr. David E. Thurston

King's College London, Institute
of Pharmaceutical Science,
School of Cancer &
Pharmaceutical Sciences, Faculty
of Life Sciences & Medicine,
Franklin-Wilkins Building,
London SE1 9NH, UK

Deadline for manuscript
submissions:

closed (28 April 2023)

Message from the Guest Editor

Dear Colleagues,

Antibody-Drug Conjugates (ADCs) have finally come of age, with fifteen examples approved world-wide, seven by the FDA alone between 2019–2022. Furthermore, there are currently over 100 ADCs in clinical trials, with further approvals anticipated in the near future. In particular, ADCs such as trastuzumab deruxtecan-nxki (Enhertu®) have made a significant difference to the lives of cancer patients, as evidenced by clinical results recently announced at the 2022 ASCO conference (*i.e.*, reducing the risk of progression or death in HER2-low metastatic breast cancer by 49% vs. chemotherapy). To celebrate this success, we are pleased to invite you to submit manuscripts for a Special Issue of the journal *Cancers*, which will focus on cutting edge ADC research and development. In this Special Issue, both original research articles and reviews are welcome, and research areas may include (but are not limited to) targeting strategies, antibody/linker/payload design, and safety issues relating to ADCs. I look forward to receiving your contributions.

Prof. Dr. David E. Thurston

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)